ABOS

Acumen Pharmaceuticals, Inc.

ABOS · CIK 1576885 · Annual (10-K) · Last 4 years

Financial Trends

Revenue
20212024
Net Income−$102M
20212024
Operating CF−$86M
20212024
Free Cash Flow
20212024

Income Statement

MetricFY 2024FY 2023FY 2022FY 2021
Revenue
Cost of Revenue
Gross Profit
R&D Expense$0.1B$0.0B$0.0B$0.0B
SG&A Expense
Operating Income$-0.1B$-0.1B$-0.0B$-0.0B
Net Income$-0.1B$-0.1B$-0.0B$-0.1B
EPS (Basic)$-1.71$-1.08$-1.06
EPS (Diluted)$-1.71$-1.08$-1.06

Balance Sheet

MetricFY 2024FY 2023FY 2022FY 2021
Total Assets$0.2B$0.3B$0.2B$0.2B
Current Assets$0.2B$0.2B$0.2B$0.2B
Cash & Equivalents$0.0B$0.1B$0.1B
Total Liabilities$0.1B$0.0B$0.0B$0.0B
Current Liabilities$0.0B$0.0B$0.0B
Stockholders' Equity$0.2B$0.3B$0.2B$0.2B

Cash Flow Statement

MetricFY 2024FY 2023FY 2022FY 2021
Operating Cash Flow$-0.1B$-0.0B$-0.0B$-0.0B
Investing Cash Flow$0.0B$-0.2B$0.0B$-0.1B
Capital Expenditures
Financing Cash Flow$0.0B$0.2B$0.0B$0.2B